Dementia with Lewy bodies: Basis of cingulate island sign

Neurology

Volumn 83, Issue 9, 2014, Pages 801-809

  Graff Radford, Jonathan ^a   Murray, Melissa E ^b   Lowe, Val J ^a   Boeve, Bradley F ^a   Ferman, Tanis J ^b   Przybelski, Scott A ^a   Lesnick, Timothy G ^a   Senjem, Matthew L ^a   Gunter, Jeffrey L ^a   Smith, Glenn E ^a   Knopman, David S ^a   Jack, Clifford R ^a   Dickson, Dennis W ^b   Petersen, Ronald C ^a   Kantarci, Kejal ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORINE 18; PITTSBURGH COMPOUND B; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CINGULATE GYRUS; CLINICAL DEMENTIA RATING; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE DURATION; EDUCATIONAL STATUS; EPISODIC MEMORY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; SEX DIFFERENCE; CASE CONTROL STUDY; DIAGNOSTIC USE; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

AGED; CASE-CONTROL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GYRUS CINGULI; HUMANS; LEWY BODY DISEASE; MALE; NEUROFIBRILLARY TANGLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 84921983758     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000734     Document Type: Article

References (40)

1. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;16:203-212.
2. McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005;65:1863-1872.
3. Nelson PT, Jicha GA, Kryscio RJ, et al. Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol 2010;257:359-366.
4. Fujishiro H, Iseki E, Higashi S, et al. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 2010;486: 19-23.
5. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69: 2197-2204.
6. Ferman TJ, Boeve BF, Smith GE, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology 2011;77:875-882.
7. Rongve A, Vossius C, Nore S, Testad I, Aarsland D. Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia. Int J Geriatr Psychiatry 2014;29:392-398.
8. WilliamsMM, Xiong C, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology 2006;67:1935-1941.
9. Graff-Radford J, Boeve BF, Pedraza O, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 2012;135:2470-2477.
10. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
11. Kantarci K, Lowe VJ, Boeve BF, et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012;33:2091-2105.
12. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-216.
13. Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: A comparative study using positron emission tomography. Neurosci Lett 1997;235:49-52.
14. Lim SM, Katsifis A, Villemagne VL, et al. The 18F-FDG PET cingulate island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009;50:1638-1645.
15. Kantarci K, Ferman TJ, Boeve BF, et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology 2012;79:553-560.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
17. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004;62:181-187.
18. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486.
19. Newell KL, Hyman BT, Growdon JH, Hedley- Whyte ET. Application of the National Institute on Aging (NIA)-Reagan Institute criteria for the neuropathological diagnosis of Alzheimer disease. J Neuropathol Exp Neurol 1999;58:1147-1155.
20. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665-680.
21. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002;15:273-289.
22. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40:2053-2065.
23. Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with Lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4:428-430.
24. Dickson DW, Crystal HA, Bevona C, Honer W, Vincent I, Davies P. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 1995;16:285-298.
25. Kantarci K, Yang C, Schneider JA, et al. Antemortem amyloid imaging and b-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012;33:878-885.
26. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996;47:462-466.
27. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001;50:358-365.
28. Perneczky R, Drzezga A, Boecker H, Forstl H, Kurz A, Haussermann P. Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement Geriatr Cogn Disord 2008;25:531-538.
29. Satoh M, Ishikawa H, Meguro K, Kasuya M, Ishii H, Yamaguchi S. Improved visual hallucination by donepezil and occipital glucose metabolism in dementia with Lewy bodies: The Osaki-Tajiri project. Eur Neurol 2010;64:337-344.
30. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alphasynuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27:1405-1410.
31. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73:273-278.
32. Zaja-Milatovic S, Keene CD, Montine KS, Leverenz JB, Tsuang D, Montine TJ. Selective dendritic degeneration of medium spiny neurons in dementia with Lewy bodies. Neurology 2006;66:1591-1593.
33. Ishii K, Sasaki M, Kitagaki H, et al. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nucl Med 1997;38:925-928.
34. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004;63:1168-1174.
35. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85-94.
36. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 2004;101: 284-289.
37. Brun A, Gustafson L. Distribution of cerebral degeneration in Alzheimer's disease: A clinico-pathological study. Arch Psychiatr Nervenkr 1976;223:15-33.
38. Cavanna AE, Trimble MR. The precuneus: A review of its functional anatomy and behavioural correlates. Brain 2006;129:564-583.
39. Galvin JE, Price JL, Yan Z, Morris JC, Sheline YI. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 2011;76:1797-1803.
40. Miller EK, Buschman TJ. Cortical circuits for the control of attention. Curr Opin Neurobiol 2013;23:216-222.